Investor Relations Home
|IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries.
|01/09/18||IRIDEX Announces Infringement Lawsuit Against Quantel|
|MOUNTAIN VIEW, Calif., Jan. 09, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (NASDAQ:IRIX) announced today that it has filed a lawsuit against Quantel Medical, S.A., Quantel USA, Inc., and Quantel, S.A. in the U.S. District Court for the Northern District of California. The lawsuit alleges that Quantel products infringe U.S. Patent No. 7,771,417, that Quantel breached an earlier agreement between the parties, and that Quantel has infringed Iridex's MicroPulse® trademark, Registration No. 45501... |
|01/08/18||IRIDEX Announces Preliminary Operational and Financial Results for 2017 Fourth Quarter and Full Year|
|MOUNTAIN VIEW, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq:IRIX) today provided preliminary operational and financial results for the fourth quarter and full year ended December 30, 2017.
Total revenue for the fourth quarter of 2017 expected to be $11.0 to $11.1 million
Total revenue for 2017 expected to be $42.3 to $42.4 million
Approximately 133 Cyclo G6 glaucoma laser systems and 10,600 G6 probes were shipped in the fourth quarter of 2017
|11/02/17||IRIDEX Announces 2017 Third Quarter Financial Results|
|MOUNTAIN VIEW, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq:IRIX) today reported financial results for the third quarter and nine months ended September 30, 2017.
Third Quarter Highlights
Record third quarter revenue of $10.9 million, an 11% year-over-year increase
Shipped 111 Cyclo G6 systems and approximately 7,800 G6 probes
Significantly expanded marketing presence at worldwide industry events:
-- European Society of Cataract and Refractive Surgeons (... |
|10/26/17||IRIDEX to Present at Upcoming Investor Conferences|
|MOUNTAIN VIEW, Calif., Oct. 26, 2017 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq:IRIX) today announced the Company plans to participate in two upcoming investor conferences.
November 9, 2017 at 1:30pm ET, IRIDEX’s management is scheduled to present at the Canaccord Genuity Medical Technologies & Diagnostics Forum in New York, NY
November 14, 2017 at 9:30am ET, IRIDEX’s management is scheduled to present at the Stifel 2017 Healthcare Conference in New York, NY
Interested par... |
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.